<DOC>
	<DOCNO>NCT00299377</DOCNO>
	<brief_summary>Randomized comparison abciximab i.v . versus i.c . patient STEMI undergo primary PCI . The hypothesis , high concentration abciximab i.c . lead improved epicardial flow , perfusion , reduction no-reflow , reduction infarct size subsequently well outcome .</brief_summary>
	<brief_title>Abciximab i.v . Versus i.c . Primary PCI Patients With STEMI</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>1 . Clinical symptom : Angina &lt; 12 h persistent Angina &gt; 30 min . 2 . ECGCriteria : STelevation &gt; 1mm ≥ 2 extremity lead STelevation &gt; 2mm ≥ 2 contiguous anterior lead 3 . Informed consent 1 . No consent 2 . Pregnancy 3 . Allergy abciximab , ASA heparin 4 . Active peptic ulcus ventriculus duodeni 5 . Active nonsuperficial bleeding 6 . Major surgical intervention , intracerebral intervention , puncture central artery &lt; 4 week 7 . Active internal bleeding 8 . Cerebrovascular complication &lt; 2 year 9 . Known coagulation disorder , thrombocytopenia 10 . Arteriovenous malformation aneurysms 11 . Severe Liver renal dysfunction 12 . Severe untreated hypertension 13 . Active vasculitis 14 . Previous thrombolysis &lt; 12 h</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>STEMI</keyword>
	<keyword>infarct size</keyword>
	<keyword>primary PCI</keyword>
	<keyword>no-reflow</keyword>
	<keyword>ST-elevation myocardial infarction</keyword>
</DOC>